Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study

Supportive Care in Cancer

Volumn 18, Issue 10, 2010, Pages 1305-1312

  Diel, Ingo J ^g   Kurth, Andreas H A ^a   Sittig, Hans Bernd ^b   Meden, Harald ^c   Maasberg, Michael ^d   Sandermann, Andreas ^e   Bergner, Raoul ^f  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b MVZ Buntenskamp   (Germany)

^c Gesundheitszentrum Fricktal   (Switzerland)

^d Hematology Oncology Center   (Germany)

^e WiSP Research Institute   (Germany)

^f KLINIKUM LUDWIGSHAFEN   (Germany)

^g NONE

Author keywords

Bisphosphonates; Bone metastases; Breast cancer; Ibandronate; Pain; Renal safety

Indexed keywords

ALENDRONIC ACID; ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CREATININE; IBANDRONIC ACID; PAMIDRONIC ACID; TRASTUZUMAB; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; GERMANY; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; NAUSEA; OBSERVATIONAL STUDY; PAIN ASSESSMENT; PATHOLOGIC FRACTURE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SKELETON; SPINAL CORD COMPRESSION;

ADMINISTRATION, ORAL; AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CREATININE; DIPHOSPHONATES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; PAIN; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 79953247346     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-009-0749-5     Document Type: Article

References (22)

1. World Health Organization (1996) WHO Guidelines: cancer pain relief. orld Health Organization, Geneva
2. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crino L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thurlimann B (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420-432
3. Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF, Tripathy D, Bergstrom B (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111:306-312 (Pubitemid 39201152)
4. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergstrom B (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399-1405
5. Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, Tripathy D, Bergstrom B (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebocontrolled phase III studies. Br J Cancer 90:1133-1137
6. Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349:1676-1679 discussion 1676-1679
7. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165-176
8. Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G, Ford JM (1996) Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol 14:2552-2559
9. Diel IJ (2007) Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review. Support Care Cancer 15:1243-1249
10. Diel IJ, Body JJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergstrom B (2004) Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40:1704-1712 (Pubitemid 38902906)
11. Ernst DS, MacDonald RN, Paterson AH, Jensen J, Brasher P, Bruera E (1992) A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Manage 7:4-11
12. Gainford MC, Dranitsaris G, Clemons M (2005) Recent developments in bisphosphonates for patients with metastatic breast cancer. Brit Med J 330:769-773
13. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335:1785-1791
14. Huskisson EC (1974) Measurement of pain. Lancet 2:1127-1131
15. Johnson KB, Gable P, Kaime EM, Luiken G, Castillos T, Hu J (2003) Significant deterioration in renal function with the new bisphosphonate, zoledronic acid. Proc Am Soc Clin Oncol 22: abstr 2968
16. O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA (1995) Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. J Clin Oncol 13:929-934
17. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655
18. Pal SK, Gupta R, Bernstein L, Mortimer J (2008) Lack of survival benefit in metastatic breast cancer with newer chemotherapy agents: The City of Hope cancer experience. ASCO 2008 Breast Cancer Symposium; Washington, DC. Abstract 5
19. Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev: CD003474
20. Pecherstorfer M, Rivkin S, Body JJ, Diel I, Bergstrom B (2006) Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Investig 26:315-322
21. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377-387
22. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735-1744